![](https://www.canaan.com/rails/active_storage/representations/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaHBBWUE9IiwiZXhwIjpudWxsLCJwdXIiOiJibG9iX2lkIn19--ecf58a9f9a7984311c0a852a45bc35d0a2e90fa2/eyJfcmFpbHMiOnsibWVzc2FnZSI6IkJBaDdCam9VWTI5dFltbHVaVjl2Y0hScGIyNXpld2M2QzNKbGMybDZaVWtpQ1RVeE1sNEdPZ1pGVkRvSmRISnBiVlE9IiwiZXhwIjpudWxsLCJwdXIiOiJ2YXJpYXRpb24ifX0=--227fdc48d0cc0381319025b1f375233c6a320fb3/civitas-transparent-background.png)
Civitas Therapeutics
Civitas is focused on developing a pulmonary delivery therapy uniquely able to address a significant unmet need for Parkinson’s patients.
Partner
Tim ShannonInvestment
Series A
Civitas is focused on developing a pulmonary delivery therapy uniquely able to address a significant unmet need for Parkinson’s patients.
Series A